-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Revolution Medicines at Buy, Raises Price Target to $179

Benzinga·05/18/2026 15:51:43
Listen to the news
Truist Securities analyst Gregory Renza assumes Revolution Medicines (NASDAQ:RVMD) with a Buy rating and raises Price Target to $179.